Viking Therapeutics Garners Analyst Support For NASH And Metabolic Programs

Analyst Upgrades02:26

Viking Therapeutics Is Winning New Fans - and Not for Its Weigh-loss Pill

MarketWatch01:30

Viking Phase 2b Study of NASH Candidate Hits Primary Endpoint

Seeking Alpha11/20 05:42

Viking Therapeutics Presents Results From Phase 2b VOYAGE Study of VK2809 in Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting 2024

PR Newswire11/20 05:03

We're Interested To See How Viking Therapeutics (NASDAQ:VKTX) Uses Its Cash Hoard To Grow

Simply Wall St11/18 21:15

3 Things You Need to Know If You Buy Viking Therapeutics Today

Yahoo Finance11/18 17:45